Patents by Inventor Torbjorn Backstrom

Torbjorn Backstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES
    Publication number: 20230117905
    Abstract: It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addition it is provided a method for preparing the pharmaceutical composition.
    Type: Application
    Filed: November 17, 2022
    Publication date: April 20, 2023
    Applicant: ASARINA PHARMA AB
    Inventors: Torbjörn Bäckström, Anders Carlsson
  • Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
    Patent number: 11534446
    Abstract: It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addition it is provided a method for preparing the pharmaceutical composition.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: December 27, 2022
    Assignee: ASARINA PHARMA AB
    Inventors: Torbjörn Bäckström, Anders Carlsson
  • 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment
    Patent number: 11026954
    Abstract: The present invention provides the steroid compound 3beta-hydroxy-5alpha-pregnan-20-one for use in treatment of Tourette's syndrome, obsessive compulsive disorder and/or gambling disorder, as well as methods for treating said disorders and pharmaceutical compositions for use in treatment of said disorders.
    Type: Grant
    Filed: September 2, 2018
    Date of Patent: June 8, 2021
    Assignee: ASARINA PHARMA AB
    Inventor: Torbjörn Bäckström
  • 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor
    Patent number: 11026953
    Abstract: The present invention provides the steroid compound 3beta-hydroxy-5alpha-pregnan-20-one for use in treatment of essential tremor, as well as methods for treating essential tremor and pharmaceutical compositions for use in treatment of essential tremor.
    Type: Grant
    Filed: September 2, 2018
    Date of Patent: June 8, 2021
    Assignee: ASARINA PHARMA AB
    Inventors: Torbjörn Bäckström, Markus Jerling
  • GABA-A ANTAGONISTS FOR TREATING SUBSTANCE WITHDRAWAL DISORDERS
    Publication number: 20210161915
    Abstract: The present disclosure provides GABAA receptor modulating steroid antagonists for use in treatment of substance withdrawal disorders as well as methods for treating said disorders and pharmaceutical compositions for use in treatment of said disorders.
    Type: Application
    Filed: April 5, 2019
    Publication date: June 3, 2021
    Applicant: ASARINA PHARMA APS
    Inventor: Torbjörn Bäckström
  • 3-Beta-Hydroxy-5-Alpha-Pregnan-20-One for Use in Treatment of Essential Tremor
    Publication number: 20190381069
    Abstract: The present invention provides the steroid compound 3beta-hydroxy-5alpha-pregnan-20-one for use in treatment of essential tremor, as well as methods for treating essential tremor and pharmaceutical compositions for use in treatment of essential tremor.
    Type: Application
    Filed: September 2, 2018
    Publication date: December 19, 2019
    Applicant: ASARINA PHARMA AB
    Inventors: Torbjörn Bäckström, Markus Jerling
  • 3-Beta-Hydroxy-5-Alpha-Pregnan-20-One for Use in Medical Treatment
    Publication number: 20190358245
    Abstract: The present invention provides the steroid compound 3beta-hydroxy-5alpha-pregnan-20-one for use in treatment of Tourette's syndrome, obsessive compulsive disorder and/or gambling disorder, as well as methods for treating said disorders and pharmaceutical compositions for use in treatment of said disorders.
    Type: Application
    Filed: September 2, 2018
    Publication date: November 28, 2019
    Applicant: ASARINA PHARMA AB
    Inventor: Torbjörn Bäckström
  • 3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders
    Patent number: 10351589
    Abstract: The invention relates to 3?-ethynyl, 3?-hydroxy, 5?-pregnan-20-oxime, represented by the following structural formula: or a pharmaceutically acceptable salt thereof, which compounds and/or salts are useful as modulators of the mammal brain excitability via the gamma-aminobutyric acid receptor-chloride ionophore (GABAA-R) complex and in the treatment of disorders such as hepatic encephalopathy, Down's syndrome and Alzheimer's disease.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: July 16, 2019
    Assignee: Umecrine Cognition AB
    Inventors: Torbjörn Bäckström, Gianna Ragagnin
  • Steroid compound for use in the treatment of hepatic encephalopathy
    Patent number: 10342804
    Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: July 9, 2019
    Assignee: Umecrine Cognition AB
    Inventors: Magnus Doverskog, Hanns Möhler, Vicente Felipo, Torbjörn Bäckström
  • Methods for treating hypersomnolence
    Patent number: 10278977
    Abstract: There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3?-ethynyl-3?-hydroxy-5?-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: May 7, 2019
    Assignee: Umecrine Cognition AB
    Inventors: Torbjörn Bäckström, Magnus Doverskog, Maja Johansson, Pontus Wasling
  • STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY
    Publication number: 20180015103
    Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 18, 2018
    Inventors: Magnus Doverskog, Hanns Möhler, Vicente Felipo, Torbjörn Bäckström
  • 3.ALPHA.-ETHYNYL, 3.BETA.-HYDROXY-5.ALPHA.-PREGNAN-20-OXIME FOR USE IN THE TREATMENT OF CNS DISORDERS
    Publication number: 20170369522
    Abstract: The invention relates to 3?-ethynyl, 3?-hydroxy, 5?-pregnan-20-oxime or a pharmaceutically acceptable salt thereof, which compounds and/or salts are useful as modulators of the mammal brain excitability via the gamma-5 aminobutyric acid receptor-chloride ionophore (GABAA-R) complex and in the treatment of disorders such as hepatic encephalopathy, Down's syndrome and Alzheimer's disease.
    Type: Application
    Filed: January 11, 2016
    Publication date: December 28, 2017
    Applicant: Umecrine Cognition AB
    Inventors: Torbjörn Bäckström, Gianna Ragagnin
  • METHODS AND MEDICAL USES
    Publication number: 20170348323
    Abstract: There is provided a method of treatment of hypersomnolence comprising administering the steroidal compound 3?-ethynyl-3?-hydroxy-5?-androstan-17-one oxime, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.
    Type: Application
    Filed: June 5, 2017
    Publication date: December 7, 2017
    Inventors: Torbjörn Bäckström, Magnus Doverskog, Maja Johansson, Pontus Wasling
  • Steroid compound for use in the treatment of hepatic encephalopathy
    Patent number: 9801894
    Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: October 31, 2017
    Assignee: Umecrine Cognition AB
    Inventors: Magnus Doverskog, Hanns Möhler, Vicente Felipo, Torbjörn Bäckström
  • PHARMACEUTICAL COMPOSITION COMPRISING 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE WITH IMPROVED STORAGE AND SOLUBILITY PROPERTIES
    Publication number: 20170258809
    Abstract: It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addition it is provided a method for preparing the pharmaceutical composition.
    Type: Application
    Filed: May 22, 2017
    Publication date: September 14, 2017
    Applicant: ASARINA PHARMA AB
    Inventors: Torbjörn BÄCKSTRÖM, Anders CARLSSON
  • Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties
    Patent number: 9687496
    Abstract: It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addition it is provided a method for preparing the pharmaceutical composition.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: June 27, 2017
    Assignee: ASARINA PHARMA AB
    Inventors: Torbjörn Bäckström, Anders Carlsson
  • STEROID COMPOUND FOR USE IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY
    Publication number: 20170056416
    Abstract: The present invention provides the steroidal compound 3?-ethynyl-3?-hydroxyandrostan-17-one oxime, or a pharmaceutically acceptable salt thereof, for use in treatment of hepatic encephalopathy.
    Type: Application
    Filed: November 15, 2016
    Publication date: March 2, 2017
    Inventors: Magnus Doverskog, Hanns Möhler, Vicente Felipo, Torbjörn Bäckström
  • STEROIDS HAVING INCREASED WATER SOLUBILITY AND RESISTANCE AGAINST METABOLISM AND METHODS FOR THEIR PRODUCTION
    Publication number: 20160272670
    Abstract: Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.
    Type: Application
    Filed: November 19, 2015
    Publication date: September 22, 2016
    Inventors: Torbjörn Bäckström, Gianna Ragagnin
  • Steroids having increased water solubility and resistance against metabolism and methods for their production
    Patent number: 9200028
    Abstract: Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: December 1, 2015
    Assignee: Umecrine Cognition AB
    Inventors: Torbjörn Bäckström, Gianna Ragagnin
  • New Steroids Having Increased Water Solubility and Resistance Against Metabolism and Methods For Their Production
    Publication number: 20150315231
    Abstract: Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.
    Type: Application
    Filed: July 10, 2015
    Publication date: November 5, 2015
    Inventors: Torbjörn Bäckström, Gianna Ragagnin